Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDP vs DHAP in Relapsed/Refractory Aggressive NHL (LY12)
NCT00078949Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2003
- Primary completion
- Jul 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of gemcitabine and rituximab in non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Canadian Cancer Trials Group. Primary endpoints: Response Rate of Patients After 2 Courses of Chemotherapy, Transplantation Rate of Patients After 2 Courses of Chemotherapy and 1 more. Started Aug 2003; status: completed.
02
Drugs
gemcitabinerituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00078949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078949.